May 2nd 2024
Phase 3b data support venetoclax as a treatment option in CLL for patients with or without B-cell receptor–associated kinase inhibitor treatment.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Efficacy Produced from Olverembatinib in Ponatinib-Resistant, T25I-Mutant CML, and Ph-Positive ALL
December 13th 2022Those with chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, and those with CML whose tumors have a T315I mutation, were found to have improved efficacy when olverembatinib was given.
Zanubrutinib Produces Superior Efficacy Over Ibrutinib in Relapsed/Refractory CLL/SLL
December 13th 2022Results from the phase 3 ALPINE trial found improved progression-free survival and overall response rate when Zanubrutinib was given to patients with chronic lymphocytic leukemia or small lymphatic leukemia vs ibrutinib.
FDA Grants BTD to Revumenib for Relapsed/Refractory KMT2Ar Acute Leukemia
December 6th 2022Revumenib, which was given a breakthrough therapy designation by the FDA, may be beneficial in the management of relapsed or refractory KMT2A-rearranged acute leukemia based on data from the phase 1 AUGMENT-101 trial.
Real-World Data Support Use of Hypomethylating Drugs in Elderly Patients With Acute Myeloid Leukemia
November 30th 2022The use of hypomethylating drugs such as azacitidine and decitabine improved outcomes for patients of advanced age with acute myeloid leukemia, according to findings from a recent retrospective study of real-world data.
FDA Grants Approval to New Dosing Regimen for Asparaginase Erwinia Chrysanthemi in ALL/LBL
November 18th 2022Patients with acute lymphocytic leukemia or lymphoblastic lymphoma can now receive asparaginase erwinia chrysanthemi at 25 mg/m2 on Monday and Wednesday followed by 50 mg/m2 on Friday, or 25 mg/m2 every 48 hours.
Ponatinib/Chemotherapy Improves MRD-Negative CRs Vs Imatinib in Ph+ ALL
November 18th 2022Among patients with Philadelphia chromosome–positive acute lymphoblastic leukemia, ponatinib plus chemotherapy yielded higher rates of minimal residual disease–negative complete remission compared with imatinib.
Approach-Oriented Coping May Improve Quality-of-Life Outcomes in Acute Myeloid Leukemia
November 7th 2022Findings from a secondary analysis highlighted an association between improved quality of life outcomes and longitudinal use of approach-oriented coping strategies in patients with acute myeloid leukemia.
Iomab-B With Subsequent Bone Marrow Transplant Meets dCR End Point in Relapsed/Refractory AML
November 1st 2022A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable complete remission compared with conventional care in elderly patients with relapsed or refractory acute myeloid leukemia.
Identification of Treatment Options and Supportive Care Strategies in AML
October 18th 2022A panel of experts convened at the 2022 NCCN: Hematologic Malignancies Conference to discuss the classification, treatment options, and supportive care strategies available for patients with acute myeloid leukemia.